Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
作者： M. J. Shale , S. A. Riley
DOI: 10.1046/J.1365-2036.2003.01648.X
关键词:
摘要: Summary Background: Non-compliance with maintenance mesalazine therapy may be a risk factor for relapse in inflammatory bowel disease, but the prevalence and determinants of non-compliance are unknown. Aim: To study patients disease. Methods: Out-patients receiving delayed-release were studied. Compliance was determined by direct enquiry analysis urine samples 5-aminosalicylic acid/N-acetyl-5-aminosalicylic acid. Potential compliance assessed. Results: Ninety-eight Forty-two (43%) reported taking < 80% their prescribed dose. Logistic regression revealed independent predictors to three-times daily dosing [odds ratio (OR), 3.1; 95% confidence interval (CI), 1.8–8.4] full-time employment (OR, 2.7; CI, 1.1–6.9). Urine from 12 (12%) contained no detectable acid, 18 (18%) had levels below those expected. Depression only predictor complete 10.5; 1.8–79.0), partial 3.7; 1.8–8.9). Self-reporting correctly identified 66% judged non-compliant on urinary drug measurement. Conclusions: is common disease. Three-times non-compliance, whilst depression associated non-compliance. detects most patients.
sci-hub.se 参考文章(46)
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) Annals of Internal Medicine. ,vol. 136, pp. 253- 253 ,(2002) , 10.7326/0003-4819-136-3-200202050-00020
S.A. Riley, V. Mani, M.J. Goodman, M.E. Herd, S. Dutt, L.A. Turnberg, Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis Gastroenterology. ,vol. 94, pp. 1383- 1389 ,(1988) , 10.1016/0016-5085(88)90677-4
Miglioli M Prantera C, Pallone F, Brunetti G, Cottone M, Grandinetti G. Prantera C, Pallone F, Cottone M, Bianchi Porro G, Ardizzone S, Petrillo M, Brignola C, Oliva L, D’Albasio G, Trallori G, Sturniolo GC, Martin A, Pera A, Barletti C, Pallone F, Fais S, Boirivant M, Lorenzetti R, Giglio L, Berto E, Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease Gastroenterology. ,vol. 103, pp. 363- 368 ,(1992) , 10.1016/0016-5085(92)90822-G
Dan Pinczowski, Anders Ekbom, John Baron, Jonathan Yuen, Hans-Olov Adami, Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study Gastroenterology. ,vol. 107, pp. 117- 120 ,(1994) , 10.1016/0016-5085(94)90068-X
J. R. Gilbert, C. E. Evans, P. Tugwell, R. B. Haynes, Predicting compliance with a regimen of digoxin therapy in family practice Canadian Medical Association Journal. ,vol. 123, pp. 119- 122 ,(1980)
STEPHEN A. ERAKER, Understanding and Improving Patient Compliance Annals of Internal Medicine. ,vol. 100, pp. 258- 268 ,(1984) , 10.7326/0003-4819-100-2-258
R. J. Dickinson, A. King, D. G. D. Wight, J. O. Hunter, G. Neale, Is continuous sulfasalazine necessary in the management of patients with ulcerative colitis? results of a preliminary study Diseases of The Colon & Rectum. ,vol. 28, pp. 929- 930 ,(1985) , 10.1007/BF02554309
P. A. M. van Hees, J. H. M. van Tongeren, Compliance to therapy in patients on a maintenance dose of sulfasalazine. Journal of Clinical Gastroenterology. ,vol. 4, pp. 333- 336 ,(1982) , 10.1097/00004836-198208000-00008
David J. Ott, Wallace C. Wu, David W. Gelfand, Extent of Colonic Visualization with the Fiberoptic Sigmoidoscope Journal of Clinical Gastroenterology. ,vol. 4, pp. 337- 342 ,(1982) , 10.1097/00004836-198208000-00009
R. CAPRILLI, A. ANDREOLI, L. CAPURSO, G. CORRAO, G. D. ALBASIO, A. GIOIENI, G. ASSUERO LANFRANCHI, I. PALADINI, F. PALLONE, V. PONTI, G. P. RIGO, F. P. ROSSINI, G. C. STURNIOLO, F. TONELLI, D. VALPIANI, , Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease Alimentary Pharmacology & Therapeutics. ,vol. 8, pp. 35- 43 ,(2007) , 10.1111/J.1365-2036.1994.TB00158.X